Current ART regimens can successfully manage HIV infection in nearly all PLWH. But what happens when a patient with HIV is coinfected with a dangerous pathogen ART alone cannot handle? Two of the most common are hepatitis B and latent tuberculosis infection.
How does ART selection and dosing need to change? Which agents should be avoided? What can a clinician do to get a patient to accept TPT — TB preventive therapy — for a disease that’s currently without symptoms?
Join Drs. Sonya Krishnan and Zachary Lorenz from the Johns Hopkins School of Medicine as we discuss the special needs of managing PLWH with coinfections — in this issue of eHIV Review.
Evaluate optimal regimens for patients living with HIV and comorbid infections such as hepatitis B and TB.
Associate Professor, Infectious Diseases Fellowship Program
Assistant Professor of Medicine
Johns Hopkins Medicine
Baltimore, MD
Infectious Diseases Fellow
Johns Hopkins University School of Medicine
Baltimore, MD
Nurse Educator
Boston Medical Center
Boston, MA
(he/him/his)
Assistant Professor
HIV, ID, and Global Medicine
Zuckerberg San Francisco General Hospital
San Francisco, California
(he/him/his)
Assistant Professor of Medicine and Pharmacology and Molecular Sciences
Division of Infectious Diseases
Division of Clinical Pharmacology
Johns Hopkins School of Medicine
Baltimore, Maryland
(she/her/hers)
0.5 hour Physicians
0.5 contact hour Nurses
Launch date: June 20, 2024
Expiration date: June 19, 2026